Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Subjects:

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Subjects:

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…<p>Confocal microscopy images of heart sections incubated with specific antibodies against VCAM-1 <b>(A)</b>, tubulin <b>(B)</b> and dynein <b>(C)</b> showed a decrease in fluorescence signals in samples from the EVs and ICs groups. …”

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects: